Do you wish to leave the site?
|Adverse reaction||TAVNEOS® (N = 166), n (%)||Standard Therapy (N = 164), n (%)|
|Nausea||39 (23.5)||34 (20.7)|
|Headache||34 (20.5)||23 (14.0)|
|Hypertension||30 (18.1)||29 (17.7)|
|Diarrhea||25 (15.1)||24 (14.6)|
|Vomiting||25 (15.1)||21 (12.8)|
|Rash||19 (11.4)||13 (7.9)|
|Fatigue||17 (10.2)||15 (9.1)|
|Upper abdominal pain||11 (6.6)||10 (6.1)|
|Dizziness||11 (6.6)||10 (6.1)|
|Blood creatinine increased||10 (6.0)||8 (4.9)|
|Paresthesia||9 (5.4)||7 (4.3)|
|Safety results||TAVNEOS® (N = 166)||Standard Therapy (N = 164)|
|No. of patients (%)||113 (68.1)||124 (75.6)|
|No. of events||233||291|
|Any serious infection|
|No. of patients (%)||22 (13.3)||25 (15.2)|
|No. of events||25||31|
|Any serious opportunistic infection—no. (%)||6 (3.6)||11 (6.7)|
|Death due to infection—no. (%)||1 (0.6)||2 (1.2)|
|Life-threatening infection—no. (%)||1 (0.6)||2 (1.2)|
Do you wish to leave the site?
Serious hypersensitivity to avacopan or to any of the excipients.
Hepatotoxicity: Serious cases of hepatic injury have been observed in patients taking TAVNEOS, including life-threatening events. Obtain liver test panel before initiating TAVNEOS, every 4 weeks after start of therapy for 6 months and as clinically indicated thereafter. Monitor patients closely for hepatic adverse reactions, and consider pausing or discontinuing treatment as clinically indicated (refer to section 5.1 of the Prescribing Information). TAVNEOS is not recommended for patients with active, untreated, and/or uncontrolled chronic liver disease (e.g., chronic active hepatitis B, untreated hepatitis C, uncontrolled autoimmune hepatitis) and cirrhosis. Consider the risks and benefits before administering this drug to a patient with liver disease.
Serious Hypersensitivity Reactions: Cases of angioedema occurred in a clinical trial, including 1 serious event requiring hospitalization. Discontinue immediately if angioedema occurs and manage accordingly. TAVNEOS must not be readministered unless another cause has been established.
Hepatitis B Virus (HBV) Reactivation: Hepatitis B reactivation, including life-threatening hepatitis B, was observed in the clinical program. Screen patients for HBV. For patients with evidence of prior infection, consult with physicians with expertise in HBV and monitor during TAVNEOS therapy and for 6 months following. If patients develop HBV reactivation, immediately discontinue TAVNEOS and concomitant therapies associated with HBV reactivation, and consult with experts before resuming.
Serious Infections: Serious infections, including fatal infections, have been reported in patients receiving TAVNEOS. The most common serious infections reported in the TAVNEOS group were pneumonia and urinary tract infections. Avoid use of TAVNEOS in patients with active, serious infection, including localized infections. Consider the risks and benefits before initiating TAVNEOS in patients with chronic infection, at increased risk of infection, or who have been to places where certain infections are common.
The most common adverse reactions (≥5% of patients and higher in the TAVNEOS group vs. prednisone group) were nausea, headache, hypertension, diarrhea, vomiting, rash, fatigue, upper abdominal pain, dizziness, blood creatinine increased, and paresthesia.
Avoid coadministration of TAVNEOS with strong and moderate CYP3A4 enzyme inducers. Reduce TAVNEOS dose when coadministered with strong CYP3A4 enzyme inhibitors to 30 mg once daily. Monitor for adverse reactions and consider dose reduction of certain sensitive CYP3A4 substrates.
TAVNEOS is available as a 10 mg capsule.
TAVNEOS (avacopan) is indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use.